Products for Research Use Only
RegisterLogin

Maropitant-13C, d3

CAT: 0804-HY-10053S1-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10053S1-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Maropitant-13C, d3 is the 13C- and deuterium labeled Maropitant. Maropitant is a selective and orally active neurokinin (NK1) receptor antagonist. Maropitant acts by blocking the binding of substance P within the emetic center and the chemoreceptor trigger zone (CRTZ) . Maropitant is highly effective in preventing vomiting[1][2].
UNSPSC
12352005
Target
Isotope-Labeled Compounds; Neurokinin Receptor
Type
Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Neuronal Signaling; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Neurological Disease; Endocrinology
Solubility
10 mM in DMSO
Smiles
[2H][13C]([2H])([2H])OC1=CC=C(C(C)(C)C)C=C1CN[C@@H]2[C@H](C(C3=CC=CC=C3)C4=CC=CC=C4)N5CCC2CC5
Molecular Formula
C31 13CH37D3N2O
Molecular Weight
472.68
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.|[2]Alvillar BM, Boscan P, Mama KR, et al. Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs. Vet Anaesth Analg. 2012 Mar;39 (2) :201-5.|[3]Benchaoui HA, Cox SR, Schneider RP et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther. 2007 Aug;30 (4) :336-44.|[4]Lesman SP, Boucher JF, Grover GS, et al. The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive days. J Vet Pharmacol Ther. 2012 Nov 20.|[5]Maropitant|[6]Ramsey DS, Kincaid K, Watkins JA et al. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs. J Vet Pharmacol Ther. 2008 Dec;31 (6) :538-43. doi: 10.1111/j.1365-2885.2008.00992.x.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-10053S-01Maropitant-d3
HY-10053-01Maropitant
HY-17410S2Iloperidone-13C, d3
HY-15463S3Imatinib-13C, d3
HY-10158S1Bosutinib-13C, d3
HY-10121S4-01Asenapine-d3,13C
HY-B0002BS2Ondansetron-13C, d3
HY-15651SAlvelestat-13C, d3
HY-113432S2Nudifloramide-13C, d3
HY-106827S1Trimegestone-13C, d3

Alternative Products

CatalogName
RM-M101101-01Maropitant-13C-D3
MBS3845903-01Maropitant
TRC-M197302-100MGMaropitant-d3
A21473-10Maropitant 10mg
GTR19192180-01Maropitant citrate
A21473-200Maropitant 200mg
A21473-5Maropitant 5mg
A21473-2Maropitant 2mg
A21473-100Maropitant 100mg

Popular Products